First and only PARP inhibitor to improve invasive disease-free survival in patients
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Acceptance based on results from the phase 3 KEYNOTE-091 trial
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Tislelizumab is now approved in nine indications in China
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Healthcare is timely and personal – and its delivery should be too
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Innate to receive $5M milestone payment from AstraZeneca
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Subscribe To Our Newsletter & Stay Updated
